Skip to main content
Premium Trial:

Request an Annual Quote

Suspension of Nasdaq Minimum Bid Price Buys Nanogen More Time for Compliance

NEW YORK (GenomeWeb News) – Due to a recent suspension by Nasdaq of certain listing requirements, Nanogen now has until Feb. 26, 2009, to gain compliance with the exchange’s $1 minimum bid rule, the firm said in a filing with the US Securities and Exchange Commission yesterday.
Nasdaq suspended the rule for all listed companies through Jan. 16, 2009. The suspension provides Nanogen with roughly three additional months to meet the minimum bid requirement, which requires its stock close at a price of at least $1 for a minimum of 10 consecutive trading days.
Nanogen was notified in May that it was not in compliance with the minimum bid rule, and the firm had until the end of November to regain compliance. It was the second time that the firm had been notified that it was not in compliance with the requirement, and the firm responded by transferring its stock from the Nasdaq Global Market to the Nasdaq Capital Market.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.